GSK
GSK
786 hedge funds and large institutions have $9.34B invested in GSK in 2017 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 303 increasing their positions, 266 reducing their positions, and 52 closing their positions.
62% more call options, than puts
Call options by funds: $137M | Put options by funds: $84.4M
62% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 52
57% more funds holding in top 10
Funds holding in top 10: 7 → 11 (+4)
16% more capital invested
Capital invested by funds: $8.06B → $9.34B (+$1.29B)
14% more repeat investments, than reductions
Existing positions increased: 303 | Existing positions reduced: 266
3% more funds holding
Funds holding: 762 → 786 (+24)
0.2% more ownership
Funds ownership: 3.41% → 3.6% (+0.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$248M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$101M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$65.1M |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$55.7M |
| 5 |
Renaissance Technologies
New York
|
+$53.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$62.9M |
| 2 |
Millennium Management
New York
|
-$59.9M |
| 3 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
-$49.1M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$40.5M |
| 5 |
Two Sigma Investments
New York
|
-$36.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFS
826
Sowell Financial Services
North Little Rock,
Arkansas
| – | -$86K | -1,701 | Closed |
|
|
JIC
827
Joel Isaacson & Co
New York
| – | -$58K | -1,209 | Closed |
|
828
Acadian Asset Management
Boston,
Massachusetts
| – | -$26K | -533 | Closed |
|
|
CG
829
Cutler Group
San Francisco,
California
| – | -$24.4K | -480 | Closed |
|
|
DIA
830
Davidson Investment Advisors
Great Falls,
Montana
| – | -$14K | -304 | Closed |
|
|
IWA
831
IBEX Wealth Advisors
Bedminster,
New Jersey
| – | -$14K | -289 | Closed |
|
|
WC
832
Whitnell & Co
Oak Brook,
Illinois
| – | -$12K | -248 | Closed |
|
|
RFWA
833
RPg Family Wealth Advisory
Burlington,
Massachusetts
| – | -$11.2K | -233 | Closed |
|
|
MBT
834
Montecito Bank & Trust
Santa Barbara,
California
| – | -$9K | -185 | Closed |
|
|
CB
835
Community Bank
Dewitt,
New York
| – | -$7K | -148 | Closed |
|
|
PAI
836
Pittenger & Anderson Inc
Lincoin,
Nebraska
| – | -$4K | -80 | Closed |
|
|
BCMIO
837
Beacon Capital Management Inc (Ohio)
Dayton,
Ohio
| – | +$51 | +1 | New |
|
|
KLWA
838
Kelly Lawrence W & Associates
Pasadens,
California
| – | +$101 | +2 | New |
|
GSK Hedge Fund Activity: Q1 2017 in Review
786 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2017, worth a combined $9.34B — up 16% from $8.06B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new GSK positions and 52 closed out — a net gain of 32 holders — while 303 added to existing stakes and 266 trimmed.
The largest buyer was Arrowstreet Capital, opening a new position worth an estimated $248M. The largest seller was D.E. Shaw & Co, cutting an estimated $62.9M.
- 786 institutional investors held GSK (GSK) as of Q1 2017, up from 762 in Q4 2016.
- Funds reported $9.34B of GSK stock for Q1 2017, up 16% quarter-over-quarter.
- 84 funds opened new GSK positions in Q1 2017 and 52 closed out, a net change of +32 holders.
- The largest GSK buyer in Q1 2017 was Arrowstreet Capital, an estimated $248M added.
- The largest GSK seller in Q1 2017 was D.E. Shaw & Co, an estimated $62.9M sold.
Based on aggregated 13F filings for Q1 2017.